1
|
Abstract
In 1997 the ICRU published Report 58 "Dose and Volume Specification for Reporting Interstitial Therapy" with the objective of addressing the problem of absorbed dose specification for reporting contemporary interstitial therapy. One of the concepts proposed in that report is "mean central dose." The fundamental goal of the mean central dose (MCD) calculation is to obtain a single, readily reportable and intercomparable value which is representative of dose in regions of the implant "where the dose gradient approximates a plateau." Delaunay triangulation (DT) is a method used in computational geometry to partition the space enclosed by the convex hull of a set of distinct points P into a set of nonoverlapping cells. In the three-dimensional case, each point of P becomes a vertex of a tetrahedron and the result of the DT is a set of tetrahedra. All treatment planning for interstitial brachytherapy inherently requires that the location of the radioactive sources, or dwell positions in the case of HDR, be known or digitized. These source locations may be regarded as a set of points representing the implanted volume. Delaunay triangulation of the source locations creates a set of tetrahedra without manual intervention. The geometric centers of these tetrahedra define a new set of points which lie "in between" the radioactive sources and which are distributed uniformly over the volume of the implant. The arithmetic mean of the dose at these centers is a three dimensional analog of the two-dimensional triangulation and inspection methods proposed for calculating MCD in ICRU 58. We demonstrate that DT can be successfully incorporated into a computerized treatment planning system and used to calculate the MCD.
Collapse
Affiliation(s)
- M A Astrahan
- Department of Radiation Oncology, Kenneth Norris Cancer Center, University of Southern California, 1441 Eastlake Avenue, Los Angeles, California 90033,
| | | | | |
Collapse
|
2
|
Ursin G, Astrahan MA, Salane M, Parisky YR, Pearce JG, Daniels JR, Pike MC, Spicer DV. The detection of changes in mammographic densities. Cancer Epidemiol Biomarkers Prev 1998; 7:43-7. [PMID: 9456242] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
We previously reported reductions in mammographic densities in women participating in a trial of a gonadotropin-releasing hormone agonist (GnRHA)-based regimen for breast cancer prevention. In our previous report, we compared (by simultaneous evaluation) three basic elements of mammographic densities. The purpose of the present study was to evaluate whether a standard (expert) method of measuring mammographic densities would detect such changes in densities and whether a novel nonexpert computer-based threshold method could do so. Mammograms were obtained from 19 women at baseline and 12 months after randomization to the GnRHA-based regimen. The extent of mammographic densities was determined by: (a) a standard expert outlining method developed by Wolfe and his colleagues (Am. J. Roentgenol., 148: 1087-1092, 1987); and (b) a new computer-based threshold method of determining densities. The results from both the expert outlining method and the computer-based threshold method were highly consistent with the results of our original (simultaneous evaluation) method. All three methods yielded statistically significant reductions in densities from baseline to the 12-month follow-up mammogram in women on the contraceptive regimen. The difference between the treated and the control group was statistically significant with the expert outlining method and was of borderline statistical significance with the computer-based threshold method. The computer-based results correlated highly (r > 0.85) with the results from the expert outlining method. Both the standard expert outlining method and the computer-based threshold method detected the reductions we had previously noted in mammographic densities induced by the GnRHA-based regimen.
Collapse
Affiliation(s)
- G Ursin
- Department of Preventive Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles 90033, USA
| | | | | | | | | | | | | | | |
Collapse
|
3
|
Abstract
PURPOSE Episcleral plaque therapy (EPT) with sealed 125I sources is widely used in the treatment of choroidal melanoma. In EPT, as elsewhere in radiotherapy, concern for normal tissue tolerance has frequently been a dose-limiting factor. The concept of conformal therapy, which seeks to improve dose homogeneity within the tumor and greatly reduce the dose to uninvolved structures may provide a solution to this problem. Radioactive sources are typically distributed uniformly over the surface of an episcleral plaque and are sometimes offset slightly from the scleral surface to reduce the dose to the sclera relative to the apex and prescribed therapeutic margin at the tumor base. Nevertheless, it is not uncommon for scleral dose to exceed the dose to the apex of intermediate to tall tumors by a factor of 4 or more. The availability of low-energy sealed sources such as 125I prompted the development of gold-backed plaques to shield noninvolved periocular tissues. The concept of shielding can be extended to include collimation of individual sources. The potential advantages of individual source collimation include reduced scleral dose, more homogeneous tumor dose, and superior shielding of adjacent normal structures such as the fovea as compared to previous plaque designs. METHODS AND MATERIALS A three-dimensional treatment-planning system has been extended to design a plaque that incorporates individually collimated 125I sources. Thermoluminescent dosimetry (TLD) and radiochromic film were used to compare calculated dose-rate distributions with measured dose rates in an acrylic phantom. RESULTS Calculations predict that source collimation in the form of a "slotted" gold plaque will achieve the purposes of the study. The collimating effect of the slots is demonstrated qualitatively using radiochromic film, and the accuracy of the calculation is demonstrated quantitatively with TLD. CONCLUSION The episcleral plaque described in this report is simpler to assemble than previous plaque designs. It produces a more homogeneous dose distribution in the tumor, reduces scleral dose by up to 50% as compared to conventional designs, and significantly reduces radiation dose to uninvolved structures adjacent to the plaque.
Collapse
Affiliation(s)
- M A Astrahan
- Department of Radiation Oncology, University of Southern California School of Medicine, Los Angeles 90033, USA
| | | | | | | |
Collapse
|
4
|
Petrovich Z, Pike MC, Boyd SD, Jozsef G, Astrahan MA, Baert L. Transurethral hyperthermia for benign prostatic hyperplasia: long term results. Int J Hyperthermia 1996; 12:595-606. [PMID: 8886887 DOI: 10.3109/02656739609027668] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
Transurethral resection of the prostate (TURP) is the only recognized treatment in patients with benign prostatic hyperplasia (BPH). Transurethral hyperthermia (TUHT) was used as an alternative treatment in patient who refused TURP. From 1987 to 1988, 21 BPH patients with moderate to severe symptoms and signs of prostatism were treated with TUHT in a phase I trial. Mean pre-treatment subjective and objective values were: total symptom score (TSS) 13.5, obstructive symptom score (OSS) 6.5, irritative symptom score (TSS) 7.0, peak flow rate (PFR) 11.6 cc/sec, post-voiding residual volume (PRV) 187 cc, and prostate volume (PV) 93 cc. TUHT was given for a total of 177 sessions (mean 8.4), each of 60 min duration at a steady state. Temperature was recorded continuously on the urethral surface, in all treatments. It ranged from Tmin 40.3 degrees C to Tmax = 49.2 degrees C and Tmean = 44.1 degrees C. The mean minimum temperature of > or = 42 degrees C was obtained in 98% of the TUHT sessions. Treatments were given on an outpatient basis without sedation or anaesthesia. Treatment tolerance was excellent with minor acute toxicity common (71% of patients), of no clinical importance and with no late complications. Of the 21 patients treated, 17 (81%) had an objective and 15 (71%) a subjective improvement recorded at 6 months post-treatment. This statistically highly significant improvement included: 61% decrease in TSS; 66% decrease in OSS; 55% decrease in ISS; 42% increase in PFR; 55% decrease in PRV; and 21% decrease in PV. Of the 17 patients with objective improvement, nine have maintained their response to TUHT for a minimum period of over six years, two relapsed at 11 and 40 months, respectively, and six patients died of cardiovascular causes maintaining their response to death. This study has demonstrated TUHT treatment efficacy with no major or clinically important toxicity in BPH patients. A relative weakness of this report is a lack of verification of objective study parameters in the patients at seven years post-treatment. Prospective randomized trials are needed to define the role of TUHT in the management of BPH patients.
Collapse
Affiliation(s)
- Z Petrovich
- Department of Radiation Oncology, University of Southern California School of Medicine, Los Angeles 90033, USA
| | | | | | | | | | | |
Collapse
|
5
|
Abstract
Episcleral plaque radiotherapy is a widely applied treatment for selected patients with uveal melanomas. This treatment is well tolerated but may produce severe late radiation complications resulting in decreased visual acuity that reduces the attractiveness of conservative therapy. The purpose of this study was to access if the addition of episcleral hyperthermia decreases late radiation complications through radiation dose reduction while maintaining high incidence of local tumor control. In a 3-year period, episcleral plaque thermoradiotherapy was given to 25 patients with uveal melanoma in a Phase I study. The mean tumor height was 6.2 mm and the mean tumor basal area was 173 mm(2). The mean radiation dose given to the tumor apex was 72.2 Gy and the mean hyperthermia temperature, given once for 45 min, was 43.5 degrees C. Of the 25 patients treated, 22 (88%) showed tumor height reduction, 2 (8%) showed no change, and 1 (4%) had an increase in tumor height. At the last follow-up (range, 20-68 months; mean, 31.2 months), a 43% mean tumor height reduction was recorded (p = 0.0002). Of the 22 patients initially showing tumor regression, 2 (9%) had subsequent tumor progression. At least ambulatory vision (>5/200) was maintained by 20 (80%) patients. Severe complications, including hemorrhagic retinal detachment and a large vitreous hemorrhage, were seen in 2 (8%) patients early in this Phase I study. The treatment program was well tolerated by the study patients. Severe late treatment toxicity was sharply reduced by limiting the mean scleral temperature to < or equal to 44 degrees C. This study employing 30% lower radiation doses, showed tumor regression in the majority of patients. Longer follow-up is needed to assess long-term treatment efficacy and late treatment complications.
Collapse
Affiliation(s)
- Z Petrovich
- Department of Radiation Oncology, University of Southern California, Los Angeles, USA
| | | | | | | | | | | |
Collapse
|
6
|
Abstract
The accurate localization of ophthalmic tumors on the scleral surface is important when calculating radiation dose to the tumor and adjacent structures from episcleral I-125 plaques. This is particularly true for tumors close to the fovea or optic nerve. A fundus view diagram of the eye is often used by ophthalmologists to describe the size and shape of the tumor perimeter as well as its geographical location on the retinal surface. There is, however, an inherent inaccuracy associated with the use of a hand drawn diagram to obtain physical measurements. A computer planning program has been developed which uses CT and a digitized photographic montage of the posterior hemisphere to estimate the size and location of posteriorly located tumors. A simple phantom was constructed to test the software and a direct comparison made between planned versus measured tumor size and location in an excised eye.
Collapse
Affiliation(s)
- M D Evans
- Medical Physics Unit, McGill University, Montreal, Canada
| | | | | |
Collapse
|
7
|
Debicki P, Astrahan MA, Ameye F, Oyen R, Baert L, Haczewski A, Petrovich Z. Temperature steering in prostate by simultaneous transurethral and transrectal hyperthermia. Urology 1992; 40:300-7. [PMID: 1384218 DOI: 10.1016/0090-4295(92)90376-8] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Localized hyperthermia (HT) is presently under investigation as a treatment for benign prostatic hyperplasia and carcinoma of the prostate (CaP). One popular approach employs a transrectal (TR) device, a directional microwave (MW) applicator inserted into the rectum and aimed at the prostate. Alternatively, in the transurethral (TU) technique, a symmetrically radiating MW antenna is placed directly within the prostatic urethra. Used individually, TR applicators are capable of effectively heating (> 42 degrees C) the prostate up to 2 cm from the rectum, whereas TU applicators selectively heat the periurethral tissue with effective radial penetration of about 0.6 cm. Neither technique is of much value in heating the anterior prostate. In general, the highest temperatures are produced in the tissue immediately adjacent to the surface of intracavitary microwave devices. However, when MW antennas are used in arrays, the resulting heating pattern can differ significantly from that of the individual antennas. Heating at depth can be selectively enhanced and "steered" by adjusting the phase relationship between the devices. Prostatic temperature profiles were measured in 6 patients treated with TR alone, TU alone, and simultaneous TR and TU heating. In the combined treatments different phase relationships between the antennas were applied. We found that a higher temperature could be produced in the center of the prostate than on the surface of either applicator for certain phase relationships, and that the temperature profiles could be changed by shifting phase. The results of these measurements are in agreement with those of a computer simulation. Based on the above data we feel the combined use of TU and TR hyperthermia may be justified in Phase I-II trials for patients with locally advanced CaP.
Collapse
Affiliation(s)
- P Debicki
- Department of Radiation Oncology, University of Southern California, School of Medicine, Kenneth Norris Cancer Hospital, Los Angeles
| | | | | | | | | | | | | |
Collapse
|
8
|
Abstract
From 1989 to 1990, 32 poor surgical risk patients with urinary retention were treated with transurethral microwave hyperthermia at the department of urology, University of Leuven in Belgium. Mean patient age was 73 years (range 58 to 90 years) and mean duration of retention was 4 weeks (range 3 to 12 weeks). Followup ranged from 13 to 82 weeks, with a mean of 31 weeks. Bilobar or trilobar hyperplasia was diagnosed in 25 patients (78%), while 7 (22%) had median lobe or median bar hypertrophy. The mean prostatic volume was 52 cc (range 25 to 150 cc). Transurethral microwave hyperthermia was given with a helical antenna at 915 MHz. once or twice per week. The mean number of transurethral microwave hyperthermia sessions was 8.9 (range 5 to 10). Each session consisted of a 60-minute treatment at a mean maximum temperature of 45.4C (range 43.7 to 47.2C), average temperature 43.9C (range 42.7 to 45.5C) and minimum temperature 42.0C (range 40.2 to 43.0C). The temperature was continuously monitored, including thermal mapping in all patients. Of the 25 patients who presented with bilobar or trilobar hyperplasia 18 (72%) were catheter-free for the duration of followup. Of the 7 median lobe or median bar patients 1 (14%) showed sufficient improvement to warrant catheter removal. This patient, however, had recurrent retention 4 months after transurethral microwave hyperthermia. In patients with bilobar and trilobar hyperplasia a strong correlation was observed among maximum temperature (p = 0.0006), average temperature (p = 0.0033) and treatment response. As expected, no such correlation existed between minimum temperature and response to treatment (p = 0.56). Our study has again demonstrated therapeutic activity in patients with benign prostatic hyperplasia treated with transurethral microwave hyperthermia. A new finding was a strong correlation between temperature and response.
Collapse
Affiliation(s)
- L Baert
- Department of Urology, University Hospital, St. Pieter, Leuven, Belgium
| | | | | | | | | | | |
Collapse
|
9
|
Petrovich Z, Astrahan MA, Luxton G, Green R, Langholz B, Liggett P. Episcleral plaque thermoradiotherapy in patients with choroidal melanoma. Int J Radiat Oncol Biol Phys 1992; 23:599-603. [PMID: 1612961 DOI: 10.1016/0360-3016(92)90017-c] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
From 1988 to 1991, 21 patients with uveal melanoma were treated in a Phase I study with episcleral plaque radiotherapy (EPRT). This irradiation was combined with localized current field episcleral hyperthermia (LCFHT). Tumor stage was: T3 = 15 (71%) and T2 = 6 (29%). Follow-up ranged from 2 to 42 months (mean 9.2 months). EPRT was given using custom built I-125 gold plaques. Radiation doses to the tumor apex ranged from 13 to 123 Gy (mean dose 70.0 Gy) given at a mean dose rate of 55 cGy/hr. LCFHT was given with 500 KHz frequency for 45 min immediately before EPRT. The temperature was controlled on the scleral surface using four thermocouples. T mean ranged from 42.5 degrees C to 45 degrees C +/- 0.5 degrees C (mean 43.4 degrees C). The study patients showed rapid tumor necrosis. A 25% mean decrease of apical tumor dimension was noted, p = 0.0007. At least ambulatory vision (greater than 5/200) was maintained by 17/21 (81%) patients. Visual acuity was seen to improve greater than 6 months post-plaque therapy in 10 (48%) study patients. This was following an intermediate decrease in visual acuity. Severe complications, including large hemorrhagic retinal detachment and large vitreous hemorrhage, were seen in two (9.5%) of the early study patients. A mean scleral temperature reduction to less than or equal to 44 degrees C +/- 0.5 degrees C resulted in good treatment tolerance and a lack of serious complications in subsequently treated patients. A Phase II prospective randomized trial comparing LCFHT with 60 versus 80 Gy EPRT dose to the tumor apex is currently being activated for patients with choroidal melanoma.
Collapse
Affiliation(s)
- Z Petrovich
- Dept. of Radiation Oncology, University of Southern California, School of Medicine, Los Angeles 90033
| | | | | | | | | | | |
Collapse
|
10
|
Abstract
During an 8-year period, 85 patients with uveal melanomas were treated with episcleral plaque radiotherapy (EPRT). The T-stage was: T1-3 (4%), T2-29 (34%) and T3-53 (62%). The mean tumor elevation was 6.1 mm. Radiation dose was prescribed at the tumor apex and at D5mm. The mean D5mm dose was 150.1 Gy (range 70.5-430 Gy) and the mean dose at the apex was 102.6 Gy (range 29.8-200 Gy). Useful vision (greater than 5/200) was maintained in 73% of patients. The 5-year actuarial survival was 88%. Metastatic disease developed in 9 (11%) patients, 6 of whom died of their disease. Basal tumor dimensions were important factors predicting metastatic disease, p = 0.002. A decrease in tumor evaluation was seen in 82%. There was a much lower incidence of decrease in tumor radial and circumferential dimensions, 47.5 and 46%, respectively, p less than 0.001. Treatment complications were common (56%), particularly in patients with large tumors (72%), p = 0.04. The incidence of complications was higher in patients treated prior to 1988 as compared to those who were treated more recently (67 vs 35%, p = 0.010). There were 13 (15%) patients who had enucleation. This included 12 treated before 1986 and 1 patient treated subsequently (46 vs 2%, p less than 0.001). In a univariate analysis, tumor height and radiation dose at D5mm were important factors predicting enucleation, p = 0.004. In a multivariate analysis, however, the most important factor predicting enucleation was treatment administration prior to 1986, p less than 0.001). A sharp decrease in the incidence of severe complications, including enucleation, as seen after 1985, is likely due to a major effort in treatment optimization.
Collapse
Affiliation(s)
- Z Petrovich
- Dept. of Radiation Oncology, University of Southern California School of Medicine, Los Angeles 90033
| | | | | | | | | |
Collapse
|
11
|
Abstract
Treatment planning for multiarc radiosurgery is an inherently complex three-dimensional dosimetry problem. Characteristics of small-field x-ray beams suggest that major simplification of the dose computation algorithm is possible without significant loss of accuracy compared to calculations based on large-field algorithms. The simplification makes it practical to efficiently implement accurate multiplanar dosimetry calculations on a desktop computer. An algorithm is described that is based on data from fixed-beam tissue-maximum-ratio (TMR) and profile measurements at isocenter. The profile for each fixed beam is scaled geometrically according to distance from the x-ray source. Beam broadening due to scatter is taken into account by a simple formula that interpolates the full width at half maximum (FWHM) between profiles at isocenter at different depths in phantom. TMR and profile data for two representative small-field collimators (10- and 25-mm projected diameter) were obtained by TLD and film measurements in a phantom. The accuracy of the calculational method and the associated computer program were verified by TLD and film measurements of noncoplanar multiarc irradiations from these collimators on a 4-MV linear accelerator. Comparison of film measurements in two orthogonal planes showed close agreement with calculations in the shape of the dose distribution. Maximal separation of measured and calculated 90%, 80%, and 50% isodose curves was less than or equal to 0.5 mm for all planes and collimators. All TLD and film measurements of dose to isocenter agreed with calculations to within 2%.
Collapse
Affiliation(s)
- G Luxton
- University of Southern California School of Medicine, Los Angeles 90033
| | | | | |
Collapse
|
12
|
Abstract
Microwave hyperthermia is presently being investigated as a treatment for alleviating the symptoms of urinary outlet obstruction associated with benign prostatic hyperplasia. Two clinical techniques using intracavitary microwave applicators are being evaluated for safety and efficacy at various institutions. The transrectal technique uses a directional microwave radiator that is inserted into the rectum adjacent to the prostate. The transurethral approach uses a symmetrically radiating applicator located within the prostatic urethra. Transrectal prostatic heating techniques require surface cooling to prevent hazardous temperatures in the intervening rectal mucosa. Since transurethral applicators radiate from within the prostatic urethra, heating is confined to the obstructive tissue immediately surrounding the applicator. Concern has been expressed regarding the possibility of thermal injury to the prostate and adjacent rectum during transurethral hyperthermia treatment. In this report we present interstitial temperature measurements of prostatic and rectal temperatures in 5 patients. Temperature was observed to decrease at a rate of about 6C/cm. outward from the applicator. No clinically significant temperature increase was observed beyond 1 cm, outside the prostatic capsule or in the rectal mucosa.
Collapse
Affiliation(s)
- M A Astrahan
- Department of Radiation Oncology, University of Southern California School of Medicine, Kenneth Norris Cancer Hospital, Los Angeles 90033
| | | | | | | | | | | |
Collapse
|
13
|
Sapozink MD, Joszef G, Astrahan MA, Gibbs FA, Petrovich Z, Stewart JR. Adjuvant pelvic hyperthermia in advanced cervical carcinoma. I. Feasibility, thermometry and device comparison. Int J Hyperthermia 1990; 6:985-96. [PMID: 2286796 DOI: 10.3109/02656739009140981] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
From 1981 to 1989, a total of 26 women with locally or regionally advanced carcinoma of the uterine cervix were treated with radiotherapy (RT) and pelvic regional hyperthermia (HT), in the Divisions of Radiation Oncology at the University of Utah Medical Center (UU) and the Kenneth Norris Jr Cancer Hospital of the University of Southern California (USC). HT was produced by the BSD-1000 HT system and the annular phased array (AA) applicator usually driven at 60-65 MHz, or the BSD-2000 HT system and the Sigma-60 (S60) applicator usually driven at 70-85 MHz. During the HT sessions acute toxicity was common, particularly because of pain within or outside the applicator, which was power-limiting in 43% of the patients overall. Pain was more easily manipulated, but more commonly power-limiting with the S60. Systemic stress was power-limiting in 22% of patients treated with the AA, but in no patients with the S60. Detailed thermal mapping and temperature analysis were performed on 26 patients. The mean overall average intratumour temperature achieved was 41 +/- 1.1 degrees C for 30 min; 5% and 35% of the monitored intratumour loci exceeded 43 degrees C and 42 degrees C, respectively. Temperatures recorded in the cervical os and proximal vagina appeared lower relative to the monitored normal structures in the region. Subacute treatment related toxicities occurred in five patients and included protracted pain (three) and superficial second degree burns (one), all of which resolved with supportive non-surgical therapy.
Collapse
Affiliation(s)
- M D Sapozink
- Division of Radiation Oncology, USC School of Medicine, Los Angeles 90033
| | | | | | | | | | | |
Collapse
|
14
|
Abstract
Episcleral plaques containing 125I sources are often used in the treatment of ocular melanoma. Within four years post-treatment, however, the majority of patients experience some visual loss due to radiation retinopathy. The high incidence of late complications suggests that careful treatment optimization may lead to improved outcome. The goal of optimization would be to reduce the magnitude of vision-limiting complications without compromising tumor control. We have developed a three-dimensional computer model for ophthalmic plaque therapy which permits us to explore the potential of various optimization strategies. One simple strategy which shows promise is to maximize the ratio of dose to the tumor apex (T) compared to dose to the macula (M). By modifying the parameters of source location, activity distribution, source orientation, and shielding we find that the calculated T:M ratio can be varied by a factor of 2 for a common plaque design and posterior tumor location. Margins and dose to the tumor volume remain essentially unchanged.
Collapse
Affiliation(s)
- M A Astrahan
- Department of Radiation Oncology, University of Southern California School of Medicine, Los Angeles 90033
| | | | | | | | | |
Collapse
|
15
|
Astrahan MA. Concerning automation and standardization of treatment records. Int J Hyperthermia 1990; 6:961. [PMID: 2250122 DOI: 10.3109/02656739009140978] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
|
16
|
Lean EK, Cohen DM, Liggett PE, Luxton G, Langholz B, Lau R, Astrahan MA, Hyden EC, Petrovich Z. Episcleral radioactive plaque therapy: initial clinical experience with 56 patients. Am J Clin Oncol 1990; 13:185-90. [PMID: 2346123 DOI: 10.1097/00000421-199006000-00001] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Between 1983 and 1987, 56 patients with choroidal melanoma were treated at the University of Southern California with episcleral plaque (RPT). There were 29 female and 27 male patients, with a mean age of 59 years. Tumor stage at diagnosis was T2 in 18 (32%) and T3 in 38 (68%) patients. The tumor height ranged from 2.9 to 15 mm (mean 6.8 mm). Radial dimensions ranged from 5 to 25 mm (mean 13.2 mm), and circumference ranged from 7 to 23 mm (mean 12.3 mm). Most (77%) patients had posteriorly located tumors, including 18% that were juxtapapillary. Custom-designed gold plaques were utilized in this study. Radioactive isotopes used were 125I for 26 procedures or 192Ir for 31 procedures. A total of 56 patients were treated, with one patient having two procedures. Radiation doses at the tumor apex ranged from 29.8 to 165.4 Gy (mean 94.5 Gy), with the dose at 5-mm depth ranging from 70.5 to 430 Gy (mean 161.5 Gy). Follow-up ranged from 29 to 57 months (mean 39 months). The overall 4-year survival was 96%, with a 91% incidence of free-of-disease progression at 4 years. The majority (84%) of patients experienced a decrease in tumor height, with 27 (48%) patients having greater than 50% decrease. Increase in tumor height was noted in 5 (9%) and no change in 4 (7%) patients. Useful vision (greater than 5/200) was observed in 59% of patients, including 21% who had improved vision. Metastatic tumor occurred in 5 (9%) patients, with a mean time to metastases of 14 months. There was a good correlation between radial tumor dimension and metastatic disease, p less than 0.001. Treatment complications were observed in 34 (61%) patients, with cataract and retinopathy being the most common. Enucleation was performed in 11 (20%) patients, with a mean time to enucleation of 14.5 months. Causative factors for enucleation were treatment complications in 6 and tumor progression in 5 patients. Enucleations were required primarily in patients with tumors greater than 8 mm in height (p = 0.009). Improved RPT techniques with three-dimensional dosimetry are needed to reduce the overall incidence of treatment complications. Adjuvant hyperthermia is being investigated in an attempt to improve tumor control in patients with larger tumors.
Collapse
Affiliation(s)
- E K Lean
- Department of Radiation Oncology, University of Southern California School of Medicine, Los Angeles 90033
| | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Sapozink MD, Boyd SD, Astrahan MA, Jozsef G, Petrovich Z. Transurethral hyperthermia for benign prostatic hyperplasia: preliminary clinical results. J Urol 1990; 143:944-9; discussion 949-50. [PMID: 1691792 DOI: 10.1016/s0022-5347(17)40146-7] [Citation(s) in RCA: 72] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
A total of 21 patients with biopsy proved benign prostatic hyperplasia underwent treatment on a pilot protocol involving intracavitary transurethral radiating microwave (630 or 915 MHz.) antenna hyperthermia. Acute and subacute toxicity was mild and consisted primarily of bladder spasm (26% of the patients), hematuria (23%) and dysuria (9%), none of which significantly limited the achievement of desired temperatures during the treatment sessions. No chronic treatment-related morbidity or mortality was observed. Detailed thermal mapping, performed along the course of the prostatic urethra, recorded temperatures of 43C or more at greater than 75% of the loci. Highly significant increases in urine flow rate, decrease in post-void residual urine capacity and decrease in frequency of nocturia were observed. A marginally significant decrease in prostate volume was noted and, with a median followup of 12.5 months, only 3 patients have required subsequent prostatic resection. Transurethral hyperthermia represents a safe and promising outpatient approach to treatment of benign prostatic hyperplasia, particularly for patients who are not candidates for conventional surgical approaches because of medical or personal reasons. Further studies with the goal of optimizing the technique appear to be warranted, although long-term results would be best evaluated with prospective phase 3 trials.
Collapse
Affiliation(s)
- M D Sapozink
- Department of Radiation Oncology, University of Southern California School of Medicine, Los Angeles
| | | | | | | | | |
Collapse
|
18
|
Abstract
Dose rate in water 1 cm transverse to an 125I seed calibrated for air kerma strength is not well established; 125I dosimetry calculations are, however, based on this constant. The specific dose constant was obtained from a series of dose rate measurements using thermoluminescent dosimetry (TLD) in a rigid geometry, full scatter acrylic phantom for individual model 6711 seeds. With a statistical precision of approximately +/- .5%, the dose rate to an infinitesimal mass of water located in acrylic at a perpendicular distance of 1 cm from the seed was found to be 0.977 cGy/h per microGy-m2/h of air kerma strength. Dose rate in a water phantom was calculated using a model that takes into account differences in both attenuation and scatter between water and acrylic. The specific dose constant in water was determined to be 0.932 (1.184 cGy-cm2/mCi-h, for the conventional exposure rate constant of 1.45 R cm2/mCi-h). This value is 7.5% less than dose rate in water from an unattenuated point source, and 9.7% less than the value commonly used for dosimetry calculations. The results suggest that most clinical 125I dosimetry estimates to date should be reconsidered for a possible reduction by about 10%. Relative scatter attenuation factors at 3 and 5 mm are also presented.
Collapse
Affiliation(s)
- G Luxton
- Department of Radiation Oncology, University of Southern California School of Medicine, Los Angeles 90033
| | | | | | | |
Collapse
|
19
|
Astrahan MA, Luxton G, Jozsef G, Kampp TD, Liggett PE, Sapozink MD, Petrovich Z. An interactive treatment planning system for ophthalmic plaque radiotherapy. Int J Radiat Oncol Biol Phys 1990; 18:679-87. [PMID: 2318702 DOI: 10.1016/0360-3016(90)90077-w] [Citation(s) in RCA: 76] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Brachytherapy using removable episcleral plaques containing sealed radioisotope sources is being studied as an alternative to enucleation in the treatment of choroidal melanoma and other tumors of the eye. Encouraging early results have been reported, but late complications which lead to loss of vision continue to be a problem. A randomized national study, the Collaborative Ocular Melanoma Study (COMS) is currently in progress to evaluate the procedure. The COMS specified isotope is 125I. Precise dosimetric calculations near the plaque may correlate strongly with complications and could also be used to optimize isotope loading patterns in the plaques. A microcomputer based treatment planning system has been developed for ophthalmic plaque brachytherapy. The program incorporates an interactive, 3-dimensional, solid-surface, color-graphic interface. The program currently supports 125I and 192Ir seeds which are treated as anisotropic line sources. Collimation effects related to plaque structure are accounted for, permitting detailed study of shielding effectiveness near the lip of a plaque. A dose distribution matrix may be calculated in any subregion of a transverse, sagittal, or coronal planar cross section of the eye, in any plane transecting the plaque and crossing the eye diametrically, or on a spherical surface within or surrounding the eye. Spherical surfaces may be displayed as 3-dimensional perspective projections or as funduscopic diagrams. Isodose contours are interpolated from the dose matrix. A pointer is also available to explicitly calculate and display dose at any location on the dosimetry surface. An interactive editing capability allows new plaque designs to be rapidly added to the system.
Collapse
Affiliation(s)
- M A Astrahan
- Department of Radiation Oncology, University of Southern California School of Medicine, Los Angeles 90033
| | | | | | | | | | | | | |
Collapse
|
20
|
Astrahan MA. Thermal mapping with multisensor probes. Strahlenther Onkol 1989; 165:746-50. [PMID: 2814815] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Affiliation(s)
- M A Astrahan
- Department of Radiation Oncology, University of Southern California, School of Medicine, Los Angeles
| |
Collapse
|
21
|
Astrahan MA, Sapozink MD, Cohen D, Luxton G, Kampp TD, Boyd S, Petrovich Z. Microwave applicator for transurethral hyperthermia of benign prostatic hyperplasia. Int J Hyperthermia 1989; 5:283-96. [PMID: 2470840 DOI: 10.3109/02656738909140455] [Citation(s) in RCA: 58] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
An applicator for heating the prostate gland using a transurethral approach is described. This technique uses three microwave antennas and a thermometry sensor attached to the outer surface of a balloon (Foley) type urological catheter. Each microwave antenna also includes a built-in thermistor to control temperature and balance power. The balloon catheter assures rapid and reproducible localization of the antennas in the prostatic urethra. The two-dimensional SAR and steady-state temperature distributions surrounding the applicator in tissue equivalent phantom are reported. Longitudinal temperature distributions measured in situ at the applicator-urethral interface and the longitudinal and radial temperature distributions measured in normal canine prostate are presented and discussed. The technique appears to be capable of elevating temperature to greater than 42 degrees C in a cylindrically symmetrical volume up to 5 cm length and 0.5 cm radial penetration surrounding the applicator.
Collapse
Affiliation(s)
- M A Astrahan
- Department of Radiation Oncology, University of Southern California School of Medicine, Kenneth Norris Cancer Hospital, Los Angeles 90033
| | | | | | | | | | | | | |
Collapse
|
22
|
Astrahan MA, Sapozink MD, Luxton G, Kampp TD, Petrovich Z. A technique for combining microwave hyperthermia with intraluminal brachytherapy of the oesophagus. Int J Hyperthermia 1989; 5:37-51. [PMID: 2921533 DOI: 10.3109/02656738909140431] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
A technique for combining microwave hyperthermia with 192Ir brachytherapy for the treatment of oesophageal carcinoma is described. This approach uses an intraluminal afterloading applicator and up to six microwave antennae to deliver both hyperthermia and brachytherapy, with minimal modification of the existing procedure for brachytherapy alone. Each microwave antenna includes a built-in thermistor to control temperature and balance power. Longitudinal temperature distributions were measured in situ from within the applicator, and at the applicator-tissue interface in vivo. Two-dimensional SAR and steady-state temperature distributions measured in muscle-equivalent phantom are presented and discussed. The technique appears to be capable of elevating tissue temperature to greater than 42 degrees C in a radially symmetric volume of length greater than 5 cm, with radial penetration of 0.5 cm. The clinical technique is relatively simple and well tolerated.
Collapse
Affiliation(s)
- M A Astrahan
- Department of Radiation Oncology, University of Southern California, School of Medicine, Los Angeles 90033
| | | | | | | | | |
Collapse
|
23
|
Abstract
Temperature measurement from within microwave interstitial antennas is a promising new development for hyperthermia. These antennas could enable the development of multipoint temperature regulation, leading to improved control of temperature distributions and therefore more effective hyperthermia treatments. In the complex environment of an antenna within a plastic catheter, measured temperatures were found to differ from the estimated local tissue temperature by up to 8 degrees C. In the design evaluated in this report the primary source of this error appears to be self-heating distal to the antenna junction, particularly in the outer copper conductor. The magnitude of self-heating is directly proportional to applied microwave power. Catheter wall thickness, tissue perfusion, and longitudinal temperature gradient also influence the measured temperature.
Collapse
Affiliation(s)
- M A Astrahan
- Department of Radiation Oncology, University of Southern California, Kenneth Norris Cancer Hospital, Los Angeles 90033
| | | | | | | |
Collapse
|
24
|
Luxton G, Astrahan MA, Liggett PE, Neblett DL, Cohen DM, Petrovich Z. Dosimetric calculations and measurements of gold plaque ophthalmic irradiators using iridium-192 and iodine-125 seeds. Int J Radiat Oncol Biol Phys 1988; 15:167-76. [PMID: 3391814 DOI: 10.1016/0360-3016(88)90362-8] [Citation(s) in RCA: 46] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
The dosimetry of ophthalmic plaques designed to hold iridium-192 or iodine-125 seeds is investigated experimentally and by means of a computer model. A phantom for thermoluminescent dosimetry (TLD) which permits measurements to within 2 mm of the plaque surface is described. TLD data are compared with model calculations that take into account the active length of the seeds, anisotropy of dose distribution from single seeds, and scatter within the phantom. An isotropic point source calculational model is accurate for clinical calculations, particularly at depths greater than 5 mm. Relative central axis dose measurements for 125I in a gold plaque are also in agreement with the model. Comparisons of 192Ir, 125I and 60Co plaques are presented. The relative advantages of using these isotopes in eye plaques are discussed.
Collapse
Affiliation(s)
- G Luxton
- Department of Radiation Oncology, University of Southern California School of Medicine, Los Angeles
| | | | | | | | | | | |
Collapse
|
25
|
Abstract
To determine the dosimetric effect of a gold plaque applicator used in 125I ophthalmic irradiation, relative dose rates at points 2-18 mm transverse to the axis of a single seed of 125I were measured in an acrylic phantom under three different measurement conditions. The detectors were 1-mm diameter X 3-mm length LiF thermoluminescent dosimeters (TLD's). Conditions corresponded to the following: (i) full scatter, (ii) the presence of an ophthalmic gold plaque, and (iii) no scatter material on the side of the seed opposite to the TLD's. The dose rate with the gold plaque is less than that with full scatter phantom. There is no significant decrease in dose rate at 2.2 mm from the seed. Dose rate is significantly reduced at greater distances. The does rate decrease ranges from 4% at 5 mm to 10% at 18 mm. The 125I seed in the gold plaque gives 3%-5% higher dose rate than in the absence of backscatter material.
Collapse
Affiliation(s)
- G Luxton
- Department of Radiation Oncology, University of Southern California, Los Angeles 90033
| | | | | |
Collapse
|
26
|
Abstract
The CGR Saturne 25 is an isocentrically mounted standing wave medical linear accelerator that produces dual-energy photon beams and a scanned electron beam with six selectable energies between 4 and 25 MeV. The highest energy photon beam is nominally referred to as 23 MV. For this beam the mean energy of the accelerated electron beam on the 1.3 radiation length (4 mm) tungsten x-ray target is found to be approximately 21 MeV, with the energy acceptance stated to be +/- 5%. The electron beam traverses a 270 degrees bending magnet upstream of the x-ray production target. The resulting bremsstrahlung beam passes through a combination steel and lead flattening filter, 4-cm maximum thickness. Dosimetric data for the 23-MV beam are presented with respect to rectangular field output factor, depth of maximum dose as a function of field size, surface and buildup dose, central axis percent depth dose, tissue-phantom ratios, beam profile, applicability of inverse square, and block transmission. Some data are also presented on the effect of different flattening filter designs on apparent beam energy.
Collapse
Affiliation(s)
- G Luxton
- University of Southern California, Department of Radiation Oncology, Kenneth Norris Jr. Cancer Hospital and Research Institute, Los Angeles 90033
| | | |
Collapse
|
27
|
Abstract
Measurements designed to separate primary and various scatter components of central axis dose of the highest energy photon beam of the CGR Saturne 25 linear accelerator are described. This beam has an unusually large output variation with field size. The measurements are performed both in air and in a water phantom, with and without an aperture external to the collimator system. Results are presented in the form of relative output factors for different field sizes due to (i) flattening filter scatter, (ii) water phantom scatter, (iii) collimator backscatter into the monitor chamber, and (iv) collimator forward scatter onto the central axis. It is found that the flattening filter is the single largest scatter component, but that each of the other factors is significant in determining the output dose per monitor unit as a function of field size.
Collapse
Affiliation(s)
- G Luxton
- University of Southern California, Department of Radiation Oncology, Kenneth Norris Jr. Cancer Hospital & Research Institute, Los Angeles 90033
| | | |
Collapse
|
28
|
Oldendorf WH, Astrahan MA. Regional silver content of radiographic film determined by x-ray fluorescence compared with optical densitometry. Med Phys 1983; 10:246-7. [PMID: 6865865 DOI: 10.1118/1.595243] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
The regional silver content of radiographic film measured by x-ray fluorescence is compared to light absorption measured by a densitometer. Silver content analysis appears to permit a greater dynamic range of useful exposure levels than does light absorption densitometry. This improvement in latitude, however, is not considered great enough to warrant development of a complex system for scanning silver distribution in radiographic applications.
Collapse
|
29
|
Astrahan MA, Oldendorf WH. Microcomputer supplementation of a liquid scintillation spectrometer. Med Phys 1983; 10:109-11. [PMID: 6843508 DOI: 10.1118/1.595264] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
|
30
|
|
31
|
Abstract
Interest in localized current field (LCF) hyperthermia tumor therapy is rapidly increasing. As yet, however, there is no integral LCF system commercially available. An experimental LCF system may be readily assembled from discrete, general purpose components, except for the tumor temperature regulating circuitry. In this article we present an LCF system designed around general purpose components and a simple circuit for temperature regulation. Comments on system safety, calibration, and performance are also included.
Collapse
|
32
|
Astrahan MA. Hyperthermia phantom. Med Phys 1979; 6:72. [PMID: 440239 DOI: 10.1118/1.594523] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
|